The abstract is read at the publisher; the summary is JClub's.
Serum CCL19 is elevated in IgG4-related disease and decreases during treatment-induced remission, distinguishing active disease from remission and tracking relapse dynamics.
- Why it matters: IgG4-related disease can be smouldering or asymptomatic, making it hard to monitor activity and detect relapse using existing markers alone.
- What they did: In 67 IgG4-RD patients, 49 healthy donors, and 21 sarcoidosis patients, 92 inflammation-associated proteins were screened; CCL19 was validated by quantitative ELISA in 80 IgG4-RD patients (including 28 with paired longitudinal samples) versus 80 matched healthy donors.
- The result: CCL19 correlated with clinical and laboratory measures of activity and severity, declined with remission, rose with subsequent relapse, and added supplemental value to IgG4 for identifying active disease.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.